GLP-1 Drugs and the Beverage Industry: What Ozempic Means for CPG Brands

The GLP-1 story in consumer goods started as a weight loss story. Ozempic, Wegovy, and their competitors were producing dramatic results for millions of Americans who had struggled with weight management for years. The cultural conversation was about before and after photos, celebrity speculation, and the ethics of pharmaceutical intervention in body image.

That framing missed the more consequential story entirely.

The more consequential story is what happens to consumer behavior when tens of millions of people go through a sustained period of appetite suppression, nutritional recalibration, and deliberate food and beverage decision making. The consumer who completes a GLP-1 cycle does not return to their prior purchasing behavior. They return with a fundamentally different relationship to what they eat and drink, a different set of product criteria, and a different willingness to pay for things that serve their goals versus things that do not.

That consumer is now a permanent feature of the CPG landscape, and their numbers are growing every quarter.

The scale of what is actually happening.

By the end of 2024, an estimated 15 million Americans had been prescribed a GLP-1 medication, with analyst projections suggesting that number could reach 30 million or more within five years as additional formulations enter the market and insurance coverage expands. Goldman Sachs research projected GLP-1 drug adoption could affect as much as 9% of the US adult population by 2030.

Those are not niche numbers. They represent a consumer behavioral shift of a scale that CPG has not seen since the low-fat movement of the 1980s, and the evidence suggests this one is more durable because it is driven by pharmacological habit formation rather than dietary trend adoption. The low-fat consumer eventually drifted back to full-fat products when the narrative changed. The GLP-1 consumer is building new habits in a context of measurable physical feedback that reinforces the behavior change in ways that willpower-based dieting never could.

The food and beverage categories most directly exposed to this shift are not always the ones that seem obvious from the outside. It is not simply that people are eating less. It is that what they are choosing to eat and drink when they do consume has shifted in specific and predictable ways that brands can build toward right now.

What GLP-1 users actually change about their consumption.

The behavioral pattern among GLP-1 users is well documented enough to be strategically actionable. Several shifts are consistent across the research.

Protein prioritization is the most significant. GLP-1 medications suppress appetite broadly, which creates a real risk of muscle mass loss if protein intake is not actively maintained. Users who are managing their health outcomes carefully actively seek high protein products to hit their daily targets in smaller overall food volumes. This is the primary driver behind Fairlife's extraordinary growth trajectory. The brand's ultra-filtered milk delivers double the protein of conventional milk in the same serving size, which is exactly the nutritional profile a GLP-1 user is looking for. Coca-Cola CEO James Quincey specifically cited GLP-1 adoption as a tailwind for Fairlife in investor communications, and the sales data supports that framing entirely.

Sugar sensitivity increases significantly among GLP-1 users. The medications blunt the reward response to sweet flavors in ways that persist beyond the active dosing period for many users. Consumers who previously had a high tolerance for sweetness in beverages find themselves gravitating toward lower sugar options not as a disciplined dietary choice but as a genuine preference shift. This is structural demand creation for the better-for-you beverage segment that does not depend on continued consumer willpower or trend momentum.

Portion consciousness becomes habitual rather than effortful. GLP-1 users who have spent months managing reduced portion sizes internalize that framework even after completing a medication cycle. They continue to seek products that deliver nutritional density in smaller volumes, that are satisfying without requiring large quantities, and that do not produce the blood sugar spikes they learned to associate with discomfort during their medication period.

Ingredient awareness accelerates. Going through a GLP-1 cycle involves a level of nutritional self-monitoring that most consumers have never practiced before. Tracking protein, managing caloric density, reading labels carefully to hit macronutrient targets: these behaviors build ingredient literacy that persists long after the prescription ends. The GLP-1 graduate is a more sophisticated CPG buyer than they were before the medication, and that sophistication applies to every category they shop.

The categories with the most to gain.

Protein beverages are the most direct beneficiary. The ready-to-drink protein shake category was already growing before GLP-1 adoption accelerated, driven by fitness culture and the broader wellness shift. GLP-1 adoption added an entirely new consumer cohort to that category, one motivated not by athletic performance but by therapeutic nutritional management. Fairlife Core Power, Premier Protein, and Orgain all saw meaningful acceleration in their growth trajectories as GLP-1 prescriptions scaled. The category is not close to saturation from this demand driver.

Better-for-you beverages broadly are capturing a consumer whose relationship with sugar has been durably altered. Prebiotic sodas, functional waters, low-sugar energy drinks, and enhanced sparkling waters all fit the profile of what a post-GLP-1 consumer reaches for when they want a beverage that feels satisfying without the sugar load they have learned to avoid. This is incremental demand on top of the wellness trend that was already driving the category, coming from a consumer with established purchasing habits and demonstrated willingness to pay a premium.

Portion-optimized formats represent an underserved opportunity. The consumer who has recalibrated their appetite around smaller quantities is a natural audience for single-serve formats, higher-density nutritional products, and beverages that deliver a complete functional benefit in a compact package. The category that figures out how to serve this consumer's portion psychology, not just their ingredient preference, is building toward a durable structural advantage that most brands have not yet identified.

The categories with the most to lose.

The categories most exposed to GLP-1 headwinds share a common profile: high sugar content, low nutritional density, and a consumption pattern built around volume and frequency rather than quality and occasion.

Traditional carbonated soft drinks are the most discussed exposure, and the concern is legitimate. A consumer whose sugar sensitivity has been durably altered by months of GLP-1 use is a structurally less reliable buyer of full-sugar soda than they were before. This does not mean the category collapses. It means the addressable market for full-sugar soft drinks is contracting at the margin in ways that compound over time as more consumers cycle through GLP-1 medications.

Alcohol is exposed in ways that are only beginning to show up in the data. GLP-1 medications appear to blunt the reward response to alcohol in addition to food for many users, with some research suggesting meaningful reductions in drinking frequency and quantity among active users. If that finding holds at scale, the alcohol category is facing a demand headwind from GLP-1 adoption that compounds on top of the economic and generational headwinds already present in the data.

What brands should be building toward.

The strategic implication of GLP-1 adoption for CPG brands is not complicated, but it requires honesty about where consumer demand is actually going rather than where it has been.

The consumer cohort growing fastest in purchasing sophistication and nutritional intentionality is the one that has been through a GLP-1 cycle or is currently in one. That cohort will represent a larger and larger share of CPG purchase volume over the next five years. The brands building products aligned with their actual nutritional priorities, high protein, lower sugar, functional density, honest ingredient profiles, are building toward a growing market. The brands that are not are building toward a shrinking one.

The window to position correctly is open right now. The GLP-1 consumer is still being underserved across most CPG categories, and the brands that identify the specific unmet need within that consumer profile and build toward it with genuine formulation credibility are the ones that will define the next generation of category leaders.

The founders Liquid Opportunities is most focused on right now are the ones asking who their consumer is becoming, not just who they have been. GLP-1 adoption is one of the clearest signals available about where that consumer is heading, and building toward it honestly and early is exactly the kind of strategic foundation that separates the brands worth backing from the ones still waiting to see how it plays out.